{
  "source": "PA-Med-Nec-Apokyn.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2228-5\nProgram Prior Authorization/Medical Necessity\nMedication Apokyn® (apomorphine) injection\nP&T Approval Date 12/2020, 12/2021, 6/2023, 6/2024, 6/2025\nEffective Date 9/1/2025\n1. Background:\nApokyn is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of\nhypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off”\nepisodes) associated with advanced Parkinson’s disease.\nCoverage will be provided for members who meet the following criteria.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Apokyn will be approved based on all of the following criteria:\na. Diagnosis of Parkinson’s disease\n-AND-\nb. Apokyn will be used as intermittent treatment for OFF episodes\n-AND-\nc. Prescribed by or in consultation with a neurologist or specialist in the treatment of\nParkinson’s disease\n-AND-\nd. Patient is currently on a stable dose of a carbidopa/levodopa-containing medication\nand will continue receiving treatment with a carbidopa/levodopa-containing\nmedication while on therapy\n-AND-\ne. Patient continues to experience ≥ 2 hours of OFF time per day despite optimal\nmanagement of carbidopa-levodopa therapy including both of the following:\n(1) Taking carbidopa/levodopa on an empty stomach or at least one half-hour or\nmore before or one hour after a meal or avoidance of high protein diet\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Dose and dosing interval optimization\n-AND-\nf. History of failure, contraindication, or intolerance to two anti-Parkinson’s disease\ntherapy from the following adjunctive pharmacotherapy classes (trial must be from\ntwo different classes):\n(1) Dopamine agonists (e.g., pramipexole, ropinirole)\n(2) Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)\n(3) Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)\n-AND-\ng. History of failure, contraindication, or intolerance to Inbrija (levodopa) inhalation\npo",
    " inhibitors (e.g., entacapone)\n(3) Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)\n-AND-\ng. History of failure, contraindication, or intolerance to Inbrija (levodopa) inhalation\npowder\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Apokyn will be approved based on the following criterion:\na. Documentation of positive clinical response to Apokyn therapy\n-AND-\nb. Patient will continue to receive treatment with a carbidopa/levodopa-containing\nmedication\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Apokyn [package insert]. Rockville, MD: MDD US Operations; June 2022.\n2. Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson's Disease:\nEfficacy and Safety of Current and New Formulations. CNS Drugs. 2019;33(9):905-918.\n© 2025 UnitedHealthcare Services, Inc.\n2\n3. Liang, TW, Tarsy D. UpToDate. Medical management of motor fluctuations and\ndyskinesia in Parkinson’s disease.2025 Apr 15. Accessed May 5, 2025.\n4. Olanow, CW et al. Apomorphine sublingual film for off episodes in Parkinson’s disease:\na randomized, double-blind, placebo-controlled phase 3 study. The Lancet Neurology.\n2020; 19(2): 135-144.\n5. Paik J. Levodopa Inhalation Powder: A Review in Parkinson's Disease. Drugs.\n2020;80(8):821-828.\nProgram Prior Authorization/Medical Necessity – Apokyn (apomorphine)\ninjection\nChange Control\n12/2020 New program.\n12/2021 Annual review with no changes to clinical",
    "Disease. Drugs.\n2020;80(8):821-828.\nProgram Prior Authorization/Medical Necessity – Apokyn (apomorphine)\ninjection\nChange Control\n12/2020 New program.\n12/2021 Annual review with no changes to clinical criteria. Updated references.\n6/2023 Annual review with no changes to clinical criteria. Updated references.\n6/2024 Annual review. Updated initial authorization duration to 12 months.\nUpdated references.\n6/2025 Annual review. Removed requirement to step through discontinued\nproduct Kynmobi. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}